Insider Selling: Achillion Pharmaceuticals Director Unloads 55,000 Shares of Stock (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) Director Gary E. Frashier unloaded 55,000 shares of the stock on the open market in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $8.00, for a total transaction of $440,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
A number of analysts have recently weighed in on ACHN shares. Analysts at Maxim Group raised their price target on shares of Achillion Pharmaceuticals from $6.00 to $22.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at Robert W. Baird upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 11th. They now have a $12.00 price target on the stock, up previously from $4.00. Finally, analysts at Deutsche Bank raised their price target on shares of Achillion Pharmaceuticals to $6.00 in a research note on Tuesday, June 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.71.
Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 3.07% during mid-day trading on Tuesday, hitting $7.58. 13,148,092 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $8.49. The stock has a 50-day moving average of $3.58 and a 200-day moving average of $3.40. The company’s market cap is $733.7 million. Achillion Pharmaceuticals also was the target of some unusual options trading activity on Monday. Traders bought 11,832 call options on the stock. This is an increase of approximately 995% compared to the average daily volume of 1,081 call options.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.16) by $0.01. Analysts expect that Achillion Pharmaceuticals will post $-0.77 EPS for the current fiscal year.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.